Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
armored CLDN18.2 nanobody CAR NK cells
- Development stage
- Preclinical
- Lead developer
- iCell Gene Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Armored CLDN18.2 nanobody CAR NK cells are an investigational allogeneic cell therapy designed to treat Claudin 18.2-positive solid tumors, particularly gastric cancer. The therapy utilizes Natural Killer (NK) cells derived from cryopreserved cord blood, engineered with a Chimeric Antigen Receptor (CAR) featuring a high-affinity VHH (nanobody) binder specific to the extracellular domain of CLDN18.2. To enhance antitumor activity and persistence in the immunosuppressive solid tumor microenvironment, the construct is armored with an IL-15/IL-15 receptor alpha (sushi domain) complex. This IL-15 signaling promotes the expansion, survival, and metabolic fitness of the NK cells. Developed using a feeder-independent expansion platform, these cells have demonstrated significant regression of gastric cancer xenografts and sustained persistence in preclinical models, supporting future clinical investigation.
- Other names
- armored CLDN18.2 CAR NK cellsCLDN18.2 nanobody CAR NK cellsCLDN-18.2 nanobody CAR NK cellsCLDN 18.2 nanobody CAR NK cellsarmored claudin 18.2 nanobody CAR NK cells
02
Targets
Claudin 18.2IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on armored CLDN18.2 nanobody CAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on armored CLDN18.2 nanobody CAR NK cells.